NA
AQST icon

Neuburgh Advisers’s Aquestive Therapeutics AQST Stock Holding History

Neuburgh Advisers’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,332
Closed -$10K – 920
2019
Q2 		$10K Hold
2,332
– – ﹤0.01% 901
2019
Q1 		$16K Buy
+2,332
New +$16.3K ﹤0.01% 892

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Neuburgh Advisers's AQST Position: Q3 2019 in Review

Neuburgh Advisers sold out of Aquestive Therapeutics (AQST) in Q3 2019, closing a stake of 2,332 shares — an estimated $10K sold.

Neuburgh Advisers first reported a position in AQST in Q1 2019 and held it in 2 quarters. The position peaked at $16K in Q1 2019. 35 funds tracked by Wall St. Rank hold AQST as of Q3 2019.

  • Neuburgh Advisers reported no remaining Aquestive Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Neuburgh Advisers sold 2,332 Aquestive Therapeutics shares in Q3 2019, an estimated $10K.
  • Neuburgh Advisers first reported a position in Aquestive Therapeutics in Q1 2019 and held it in 2 quarters.
  • Neuburgh Advisers's Aquestive Therapeutics position peaked at $16K in Q1 2019.
  • 35 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.